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INTRODUCTION
A variety of gene delivery methods, such as liposomes, lentiviruses, and adenoviruses, have been evaluated in cardiomyocytes differentiated from stem cells. Adeno-associated viral (AAV) vectors have an established track record of efficient and safe transgene delivery. A recent report documented in total 92 registered clinical trials with AAV worldwide 1 and the number continues to increase. Several unique properties distinguish AAV from other vectors for targeted gene delivery, including serotype-specific tropisms toward certain tissues and sustained epi-chromosomal expression with attenuated oncogenic risk. 2, 3 A comprehensive in vitro survey of AAV transduction efficiency on various mammalian cell types has been conducted. 4 Though previous study has proven the feasibility of AAV to transduce stem cell differentiated cardiomyocytes on a small scale, 5 an extensive optimization of AAV on stem cell-derived cardiomyocytes has not been reported. Here we compared the transduction efficiency of seven commonly used AAV serotypes in low-purity induced pluripotent stem cell (iPSC) differentiated cardiomyocytes, and all tested serotypes demonstrated preferential cardiomyocytes transduction in comparison to noncardiomyocytes, with AAV1 showing the highest cardiac transduction efficiency. This unique tropism was subsequently utilized to improve cardiomyocyte purity, by delivering a neomycin resistance gene to facilitate simple G418 selection. This study demonstrated that viral intrinsic tissue tropism could be exploited to enrich certain stem cell derivatives to benefit downstream applications.
MATERIALS AND METHODS iPSC maintenance and cardiac induction
The iPSC line designated UC3-4 was used for this study. The derivation and maintenance of iPSCs was described previously. 6 Briefly, undifferentiated iPSCs were maintained under feederfree condition with daily change of mTeSR-1 medium ( 8 The culture medium was removed from the CS5 and exchanged with the transfection medium; cells were subsequently incubated 6-15 hr at 37 -1°C and 5% -1% CO 2 . The transfection medium was removed from the CS5 and replaced by fresh exchange medium (DMEM, 1% penicillin/streptomycin) before a 3-day incubation at 37 -1°C and 5% -1% CO 2 . The cells of the CS5 transfected were then harvested. Depending on serotype, the supernatant was precipitated at 5 -3°C overnight with PEG and centrifuged. The supernatant was discarded and the PEG-pellet was resuspended in Tris-buffered saline before benzonase digestion. AAV particles were extracted from the cell pellet with Hank's balanced salt solution after benzonase digestion.
The viral suspension was centrifuged and the vector-containing supernatant was loaded on a step density CsCl gradient and centrifuged at 28,000 rpm for 24 hr at 15°C. The full particle band was collected and centrifuged at 38,000 rpm for 48 hr. The enriched full particle band was collected. The viral suspension was then subjected to four successive rounds of dialysis in a Slide-a Lyzer cassette against phosphatase buffered saline (PBS). The purified vector was collected, sampled for viral genome (vg) titer and purity assay, and stored at less than -70°C in polypropylene low-binding cryovials.
Cell transduction
For AAV transduction, cardiac differentiated iPSC cultures, a heterogeneous population containing 20%-40% of cardiomyocytes, were dissociated by 0.25% Trypsin-EDTA (Cat No. 15040-066; Life Technologies) and replated in 24-well plate in maintenance medium with AAV at designated multiplicity of infections (MOIs). The next day, 250 ll fresh medium was added to each well. Medium was changed every 48 hr.
To determine the optimal MOI for serotype comparison, a preliminary dose escalation experiment was conducted with AAV6 and 8, MOI ranging from 10, 100, 1000, and 10,000 vg/cell (Supplementary Fig. S1 ; Supplementary Data are available online at www.liebertpub.com/humc). MOI at 1000 yielded a robust GFP transgene expression 6 days postinitial transduction, and the difference of mean fluorescence intensity (DMFI) between GFP + /cTnT + population and GFP -/ cTnT -population was within 3 logs (16,425 and 6,201 units, AAV6 and 8, respectively), while GFP transgene signal at MOI 10,000 was too strong and saturated the detection range (DMFI 83,380 and 22,852 units, AAV6 and 8, respectively). Based on this result, MOI of 1000 vg/cell was chosen for serotype comparison experiment ( Supplementary  Fig. S1 ).
Immunocytochemical staining
Cells transduced with AAV GFP were seeded onto Matrigel-coated coverslips for imaging. Attached cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton-X (Cat No: X100; Sigma-Aldrich) in PBS. After blocking with DAKO serum-free protein block at room temperature for 2 hr, samples were probed with primary antibodies against alpha-sarcomeric actinin (Cat No: PA5-17308; Thermo Scientific, Rockland, IL) at 4°C overnight. On the second day, samples were developed with TxRed-conjugated anti-mouse IgG for visualization. All images were captured with a Nikon A1 confocal microscope (Nikon Instrument Inc., Melville, NY) and processed with Nikon Elements analysis software (advanced research, Version 3.2 64bit; Nikon Instrument Inc.).
Flow cytometry analysis
Cells were dissociated with 0.25% Trypsin-EDTA, fixed with 4% paraformaldehyde, and permeabilized with 0.1% Triton-X in PBS with 5% BSA. Cardiac troponin T antibody (Thermo Scientific) was prelabeled with Zenon Alexa Fluor 647 mouse IgG labeling reagent (Life Technologies) following the manufacturer's instructions. The prelabeled cardiac troponin antibody was used to probe the cells. After PBS wash, labeled cells were analyzed by FACS CantoII cell analyzer (BD Bioscience, San Jose, CA) equipped with BD FACSDiva software. All data were processed by FlowJo (V10; Flowjo LLC, Ashland, OR).
Statistics
Data were analyzed with GraphPad Prism (Version 6; GraphPad Software, La Jolla, CA). AAV serotype comparison was analyzed by one-way ANOVA with Bonferroni's post hoc analysis (significantly different at p < 0.05). Cardiomyocyte enrichment data was analyzed by unpaired t-test (two-tailed, significantly different at p < 0.05).
RESULTS

Cardiomyocyte induction of human iPSCs
Human iPS cell line UC3-4 6 was differentiated into cardiac lineage as described previously. 7 Spontaneously contracting cell clusters could be observed between days 10 and 14, and the beating area gradually increased over time. However, the efficiency of cardiac induction varied among different experiments, ranging from 20% to 80% as indicated by cardiac troponin T (cTnT) flow cytometry analysis (Supplementary Fig. S2) .
Various AAV serotypes demonstrate robust cardiac tropism in vitro AAV's cardiac tropism is well documented in vivo 9 but not in vitro. Here, the heterogeneous population differentiated from iPSCs provided an opportunity to assay AAV's tissue tropism for cardiomyocytes versus noncardiomyocytes. From 14 to 21 days postcardiac induction, the mixed iPSC derivatives were replated in multiwell plates to ensure uniform cellular composition for downstream comparison. Initially, cardiomyocytes constitute approximately 20% of total population (Fig.  1B) . In order to determine the optimal experimental condition, a panel of AAV serotypes expressing GFP driven by CMV promoter (Fig. 1A) was added at various MOIs. Transduction efficiency, evident by GFP expression, was separately calculated within cardiac (cTnT + ) and noncardiac (cTnT -) populations (Fig. 1B and C) . Though higher MOIs resulted in increased transduction efficiency in both populations, AAV preferentially transduces cardiomyocytes, as evident by the higher percentage of GFP-positive cardiomyocytes in all tested conditions (Fig. 1D) . The best separation between cardiac and noncardiac populations was with AAV1 at an MOI of 1000 vg/cell, which labeled 79.2% of cardiomyocytes and only 14.6% of noncardiomyocytes (Fig. 1D) , recapitulating the cardiac tropism reported in vivo. Live cell imaging also confirmed that GFP expression was localized to spontaneously contracting myocyte foci (see Supplementary Videos S1 and S2).
AAV1 demonstrates the highest transduction efficiency among a panel of AAV serotypes
To closely monitor in vitro transduction efficiency and provide statistical power, the AAV transduction experiment was repeated, with an MOI of 1000 in triplicates instead of the entire range. The result confirmed AAV1 as the best serotype in transducing cardiomyocytes with an efficiency of 77.5% -1%, followed by AAV2 and AAV6 with efficiencies of 52.9% -1% and 45.8% -3%, respectively. AAV8 and AAV10 were the least efficient, with an efficiency of 5.82% -0.6% and 2.46% -0.2%, respectively (Fig. 2) .
Harnessing the cardiac tropism of AAV1 for targeted gene delivery
The fact that AAV preferentially transduces cardiomyocytes prompted us to hypothesize that the intrinsic tissue tropism of AAV could be exploited to enrich cardiomyocytes by specifically delivering a genetic selection marker. To test this hypothesis, a plasmid (pTR-UF-11) containing GFP and neomycin resistance genes was packaged into the most efficient AAV1 (Fig. 3A) . A dose escalation experiment using AAV1-pTR-UF-11 confirmed that an MOI at 1000 vg/cell was optimal to separate the cardiac and noncardiac populations, transducing 63.6% of cardiomyocytes and 22.7% of noncardiac cells (Fig. 3B) . Therefore, 1000 vg/cell AAV1-pTR-UF-11 was delivered to a heterogeneous population differentiated from iPSCs. After stabilizing transgene expression for 6 days, transduced cells were exposed to 250 lg/ml G418 (Fig. 3A) . For an experiment with 26% cardiomyocytes, 2-fold enrichment was achieved ( Fig. 4A ; from 26.7% to 57.2%) after 2-week drug selection. Immunocytochemistry confirmed the enrichment, using co-localization of GFP expression and a-actinin staining (Fig. 4B) .
DISCUSSION
Intracoronary administration of AAV1 carrying the sarcoplasmic reticulum Ca 2 + -ATPase (SERCA2a) was the first clinical study using AAV for cardiovascular diseases. 10 Our data suggest that multiple AAV serotypes can efficiently transduce iPSC-derived cardiomyocytes in vitro, with AAV1, AAV2, and AAV6 showing good cardiomyocyte affinity. Though evidence collected in vitro cannot predict viral in vivo performance, it has been documented that both AAV1 and AAV6 are preferred strains for clinical and several preclinical large animal studies (see review 11 ). Cell transplantation has emerged as a promising treatment for a wide range of heart diseases, including bradycardia, ischemic heart disease, and dilated cardiomyopathy.
12-15 Although cell 16 boosts the secretion of paracrine factors, 17 and augments post-transplantation cell engraftment and survival. 18 In contrast to beneficial effects, transplanted cells could potentially inflict fatal adverse effects such as ventricular tachycardia. 13 In that case, genetic modification in the form of a ''suicide gene'' might be employed as a safeguard to eliminate deleterious outcomes. 19 The current study demonstrates that AAV is an effective gene delivery vehicle to target cardiomyocytes differentiated from human pluripotent stem cells. Together with its extraordinary safety profile and the ability to support long-term transgene expression, these lines of evidence justify AAV to be considered as the preferred gene delivery modality for ex vivo gene therapy, to modify donor cardiomyocytes.
In addition to its pleiotropic tissue substrates, different serotype variants demonstrate preference toward certain tissues. 9 This feature has been utilized in vivo for tissue-specific gene delivery to minimize off-target effects. AAV's serotype is largely determined by the variation of viral capsid proteins, which dictates the required cell surface receptors for AAV's attachment and internalization. 9 For example, the primary receptor for AAV2 is heparin sulfate proteoglycans, while AAV1, 5, 20 Widely shared cell surface receptors probably lack the tissue specificity required to account for the observed tissue tropism. It has been proposed that steps after viral internalization may be more important determinant of cellular permissiveness to AAV. The fact that all serotype variants demonstrate preference for postmitotic cells may be explained by these cells' attenuated DNA damage response-a critical step to eliminate foreign genetic material such as AAV. 21 In our experiments, AAV's cardiac tissue tropism was reproduced with all tested serotypes, reflected by the preferential transduction of cardiomyocytes in comparison to noncardiomyocytes (e.g., smooth muscle and endothelial cells derived from a common cardiac precursor 22 ) that retain mitotic activity. Thus, the observed cardiac tropism is consistent with previous report on neonatal rat cardiomyocytes, 21 and may be adequately explained by the difference in mitotic capacity between cardiomyocytes and noncardiomyocytes at this developmental stage (6-8 weeks).
Insights gained from developmental biology have greatly improved the cardiac induction efficiency, 7, 23 but the consistent generation of high-purity cardiomyocytes from human pluripotent stem cells in large quantity still presents a major hurdle for various applications. Several enrichment methods have been described to selectively purify cardiomyocytes based on genetic selection, 24 cell surface marker or mitochondria labeling, 25 metabolic selection, 26 or 3D cell culture. 27 The observed intrinsic cardiac tropism of AAV prompted us to exploit this property, as a proof of concept, for cardiac cell enrichment. A neomycin resistance gene was administered via the most efficient AAV serotype AAV1 to facilitate G418 selection. Two-week G418 selection achieved 2-fold enrichment in one experiment, in which cardiomyocytes initially constitute 27% of total population. Compared to genetic selection, 24 mitochondria labeling, 25 or surface marker-based cell sorting, [28] [29] [30] (A) FACS analysis of AAV1-pTR-UF11-transduced iPSC derivatives with and without G418 selection. Cells were probed for cardiac-specific cTnT (n = 3 for each conditions; *p = 0.0007). (B) Immunofluorescent staining of AAV1-pTR-UF11-transduced iPSC derivatives with and without G418 selection. Cells were probed for cardiac-specific a-actinin. Color images available online at www.liebertpub.com/humc rAAVs pose a lower risk for insertional tumorgenesis 35 compared with other vehicles such as lentivirus. Second, in contrast to surface marker sorting and intracellular dye staining, no antibody or dye labeling is involved and the output is not constrained by flow cytometry. As a result, large-scale cardiomyocyte enrichment might be achieved in a cost-effective and timely manner. It is conceivable that the selection efficiency could be further optimized by combining cardiacspecific promoter into the current strategy, as suggested by a recent study utilizing AAV9 combined with cTnT promoter to precisely target Cre recombinase to cardiomyocytes following systemic delivery. 36 
